Generic Content-Olaparib , Manufactured By:Astrazeneca

Olaparib is an FDA-approved targeted therapy for cancer. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase, an enzyme involved in DNA repair. It acts against cancers in people with hereditary BRCA1 or BRCA2 mutations, which include some ovarian, breast, and prostate cancers.

Olaparib is indicated as monotherapy for the treatment of metastatic or locally advanced cancer in patients whose tumors are resistant.